Voluntary announcement - first-in-human phase i study data of GB268 presented at the esmo congress 2026
Filed with HKEX · Stock code 6998 ·
6ix is reading this filing.
View original source (HKEXnews)Edding Genor Group Holdings Limited on 6ix
Earlier from Edding Genor
- Next Day Disclosure Return
- Voluntary announcement - IND approval from the NMPA for Phase II clinical trial of GB268 in colorectal cancer
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow Edding Genor into a list and get an email when it puts out news.
Follow Edding Genor